Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Endostar + Envafolimab in Elderly Locally Advanced Nasopharyngeal Carcinoma
NCT06055816Phase 2Active, not recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of endostar, envafolimab in nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Started Oct 2023; status: active, not recruiting.
02
Drugs
endostarenvafolimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06055816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055816.